M. Novak & V. Vetvicka (2008-10-09). “β-Glucans, History, and the Present: Immunomodulatory Aspects and Mechanisms of Action”. Journal of Immunotoxicology5 (1): 47-57. doi:10.1080/15476910802019045.
Djordje B. Zeković, Stefan Kwiatkowski, Miroslav M. Vrvić, Dragica Jakovljević & Colm A. Moran (2005). “Natural and Modified (1→3)-β-D-Glucans in Health Promotion and Disease Alleviation”. Critical Reviews in Biotechnology25 (4): 205-230. doi:10.1080/07388550500376166.
Per Sikora, Susan M. Tosh, Yolanda Brummer, Olof Olsson (2012). “Identification of high β-glucan oat lines and localization and chemical characterization of their seed kernel β-glucans.”. Food Chemistry137: 83-91. doi:10.1016/j.foodchem.2012.10.007. PMID23199994.
Julia J. Volman, Julian D. Ramakers, Jogchum Plat (2008). “Dietary modulation of immune function by β-glucans”. Physiology & Behavior94 (2): 276-284. doi:10.1016/j.physbeh.2007.11.045.
Mcintosh, M (19 October 2004). “Curdlan and other bacterial (1→3)-β-D-glucans”. Applied Microbiology and Biotechnology68 (2): 163-173. doi:10.1007/s00253-005-1959-5.
Jane Teas (1983). “The dietary intake of Laminaria, a brown seaweed, and breast cancer prevention”. Nutrition and Cancer4 (3): 217-222. doi:10.1080/01635588209513760. PMID6302638.
Taichi Usui, Yoshio Iwasaki, Takashi Mizuno, Motohiro Tanaka, Kenkichi Shinkai, Masao Arakawa (1983). “Isolation and characterization of antitumor active β-d-glucans from the fruit bodies of Ganoderma applanatum”. Carbohydrate Research115: 273-280. doi:10.1016/0008-6215(83)88159-2.
Solomon P. Wasser, Alexander L. Weis (1999). “Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective”. Critical Reviews in Immunology19 (1): 65-96. doi:10.1615/CritRevImmunol.v19.i1.30. PMID9987601.
Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, Heard S, Keroack M, Caushaj P, Benotti P. (1994). “A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients”. Arch Surg129 (11): 1204-1210. doi:10.1001/archsurg.1994.01420350102014. PMID7979954.
E. Patchen Dellinger, MD; Timothy J. Babineau, MD; Paul Bleicher, MD, PhD; et al (1999). “Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations”. Arch Surg134 (9): 977-983. doi:10.1001/archsurg.134.9.977. PMID10487593.
S. Tsukagoshi, Y. Hashimoto, G. Fujii, H. Kobayashi, K. Nomoto, K. Orita (1984). “Krestin (PSK)”. Cancer Treatment Reviews11 (2): 131-155. doi:10.1016/0305-7372(84)90005-7. PMID6238674.
Feng Hong, Jun Yan, Jarek T. Baran, Daniel J. Allendorf, Richard D. Hansen, Gary R. Ostroff, Pei Xiang Xing, Nai-Kong V. Cheung and Gordon D. Ross (2004). “Mechanism by Which Orally Administered β-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models”. J Immunology173 (2): 797-806. doi:10.4049/jimmunol.173.2.797. PMID15240666.
Yoshiyuki Adachi「(1→3)-β-D-グルカン受容体Dectin-1の自然免疫及び抗腫瘍免疫活性作用と真菌感染防御における役割」『Trends in Glycoscience and Glycotechnology』第19巻、2007年、195-207頁、doi:10.4052/tigg.19.195。
Shah, Vaibhav B.; Huang, Yongcheng; Keshwara, Rohan; Ozment-Skelton, Tammy; Williams, David L.; Keshvara, Lakhu (2008-03-01). “β-Glucan Activates Microglia without Inducing Cytokine Production in Dectin-1-Dependent Manner”. The Journal of Immunology180 (5): 2777–2785. doi:10.4049/jimmunol.180.5.2777. ISSN0022-1767.
Babineau, TJ; Hackford A; Kenler A; Bistrian B; Forse RA; Fairchild PG; Heard S; Keroack M et al. (November 1994). “A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients”. Archives of surgery (Chicago, Ill. : 1960) (アメリカ) 129 (11): 1204-1210. doi:10.1001/archsurg.1994.01420350102014. ISSN0004-0010. PMID7979954.
Dellinger, EP; Babineau TJ, Bleicher P, Kaiser AB, Seibert GB, Postier RG, Vogel SB, Norman J, Kaufman D, Galandiuk S, Condon RE (September 1999). “Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group”. Archives of surgery(英語版) (シカゴ, Ill. : 1960) (アメリカ: アメリカ医学会) 134 (9): 977-983. doi:10.1001/archsurg.134.9.977. PMID10487593.
S.C. Jaehrig, S. Rohn, L.W. Kroh, L-G. Fleischer, and T. Kurz (2007). “In Vitro Potential Antioxidant Activity of (1→3),(1→6)-β-d-Glucan and Protein Fractions from Saccharomyces cerevisiae Cell Walls”. J. Agric. Food Chem.55 (12): 4710-4716. doi:10.1021/jf063209q.
R W Kirby, J W Anderson, B Sieling, E D Rees, W J Chen, R E Miller, and R M Kay (1981). “Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men.”. The American Journal of Clinical Nutrition34 (5): 824-829. PMID6263072.
Per Sikora, Susan M. Tosh, Yolanda Brummer, Olof Olsson (2012). “Identification of high β-glucan oat lines and localization and chemical characterization of their seed kernel β-glucans.”. Food Chemistry137: 83-91. doi:10.1016/j.foodchem.2012.10.007. PMID23199994.
Jane Teas (1983). “The dietary intake of Laminaria, a brown seaweed, and breast cancer prevention”. Nutrition and Cancer4 (3): 217-222. doi:10.1080/01635588209513760. PMID6302638.
Solomon P. Wasser, Alexander L. Weis (1999). “Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective”. Critical Reviews in Immunology19 (1): 65-96. doi:10.1615/CritRevImmunol.v19.i1.30. PMID9987601.
Geraldine F Keogh, Garth JS Cooper, Tom B Mulvey, Brian H McArdle, Graeme D Coles, John A Monro, and Sally D Poppitt (2003). “Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men”. The American Journal of Clinical Nutrition78 (4): 711-718. PMID14522728.
Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, Heard S, Keroack M, Caushaj P, Benotti P. (1994). “A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients”. Arch Surg129 (11): 1204-1210. doi:10.1001/archsurg.1994.01420350102014. PMID7979954.
E. Patchen Dellinger, MD; Timothy J. Babineau, MD; Paul Bleicher, MD, PhD; et al (1999). “Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations”. Arch Surg134 (9): 977-983. doi:10.1001/archsurg.134.9.977. PMID10487593.
Kirmaz C, Bayrak P, Yilmaz O, Yuksel H. (2005). “Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study”. European Cytokine Network16 (2): 128-134. PMID15941684.
S. Tsukagoshi, Y. Hashimoto, G. Fujii, H. Kobayashi, K. Nomoto, K. Orita (1984). “Krestin (PSK)”. Cancer Treatment Reviews11 (2): 131-155. doi:10.1016/0305-7372(84)90005-7. PMID6238674.
Feng Hong, Jun Yan, Jarek T. Baran, Daniel J. Allendorf, Richard D. Hansen, Gary R. Ostroff, Pei Xiang Xing, Nai-Kong V. Cheung and Gordon D. Ross (2004). “Mechanism by Which Orally Administered β-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models”. J Immunology173 (2): 797-806. doi:10.4049/jimmunol.173.2.797. PMID15240666.
Babineau, TJ; Hackford A; Kenler A; Bistrian B; Forse RA; Fairchild PG; Heard S; Keroack M et al. (November 1994). “A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients”. Archives of surgery (Chicago, Ill. : 1960) (アメリカ) 129 (11): 1204-1210. doi:10.1001/archsurg.1994.01420350102014. ISSN0004-0010. PMID7979954.
Dellinger, EP; Babineau TJ, Bleicher P, Kaiser AB, Seibert GB, Postier RG, Vogel SB, Norman J, Kaufman D, Galandiuk S, Condon RE (September 1999). “Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group”. Archives of surgery(英語版) (シカゴ, Ill. : 1960) (アメリカ: アメリカ医学会) 134 (9): 977-983. doi:10.1001/archsurg.134.9.977. PMID10487593.
Dellinger, EP; Babineau TJ, Bleicher P, Kaiser AB, Seibert GB, Postier RG, Vogel SB, Norman J, Kaufman D, Galandiuk S, Condon RE (September 1999). “Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group”. Archives of surgery(英語版) (シカゴ, Ill. : 1960) (アメリカ: アメリカ医学会) 134 (9): 977-983. doi:10.1001/archsurg.134.9.977. PMID10487593.
Shah, Vaibhav B.; Huang, Yongcheng; Keshwara, Rohan; Ozment-Skelton, Tammy; Williams, David L.; Keshvara, Lakhu (2008-03-01). “β-Glucan Activates Microglia without Inducing Cytokine Production in Dectin-1-Dependent Manner”. The Journal of Immunology180 (5): 2777–2785. doi:10.4049/jimmunol.180.5.2777. ISSN0022-1767.
Babineau, TJ; Hackford A; Kenler A; Bistrian B; Forse RA; Fairchild PG; Heard S; Keroack M et al. (November 1994). “A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients”. Archives of surgery (Chicago, Ill. : 1960) (アメリカ) 129 (11): 1204-1210. doi:10.1001/archsurg.1994.01420350102014. ISSN0004-0010. PMID7979954.
V. Vetvicka, K. Terayama, R. Mandeville, P. Brousseau, B. Kournikakis, G. Ostroff, Québec Canada, Alberta Canada (2002). “Pilot Study : Orally-administered yeast β1,3-glucan prophylactically protects against anthrax infection and cancer in mice”. Journal of the American Nutraceutical Association5: 16-20. ISSN1521-4524.